{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:17:32Z","timestamp":1778660252490,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To compare the inhibitory effects of dovitinib and bevacizumab for treatment of corneal neovascularization (CNV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Thirty-nine adult female Sprague Dawley rats weighing 180 to 250 g were used. CNV was induced by silver nitrate in the right eye of each rat. After the chemical burn, the animals were randomized into 5 groups. Group 1 did not receive any chemical substance. Group 2 received dimethyl sulfoxide, group 3 received bevacizumab 5 mg\/mL, group 4 received dovitinib 5 mg\/mL, and group 5 received bevacizumab 5 mg\/mL + dovitinib 5 mg\/mL topically administered twice daily for 14 days. On the 14th day, slit-lamp examination was performed, and anterior segment photographs were taken. The corneal neovascular area was measured on photographs as the percentage of the cornea's total area using computer imaging analysis. The corneal sections were stained with hematoxylin and eosin for histopathological examination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A statistically significant decrease in the percentage of CNV was found in all treatment groups (group 3, group 4, and group 5) compared with the control group (group 1) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). A statistically significant difference in the percentage of CNV was found among group 3, group 4, and group 5 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). The percentage of CNV in group 4 was significantly higher than that in group 3 and group 5 (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>1<\/jats:sub> = 0.004; <jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>2<\/jats:sub> = 0.006). There was no statistically significant difference in the percentage of CNV between group 3 and group 5 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.228).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Dovitinib is a newly developed multitargeted tyrosine kinase inhibitor. Topical administration of dovitinib effectively inhibited CNV, but this effect of dovitinib was found less than topical bevacizumab.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000002012","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T04:29:19Z","timestamp":1560140959000},"page":"1161-1168","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model"],"prefix":"10.1097","volume":"38","author":[{"given":"Berna","family":"Sahan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Yeditepe University, Istanbul, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferda","family":"Ciftci","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Yeditepe University, Istanbul, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signem","family":"Eyuboglu","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medicine, Istinye University, Istanbul,Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Yaba","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, School of Medicine, Yeditepe University, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayram","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medicine, Yeditepe University, Istanbul, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belk\u0131s Ilgaz","family":"Yalvac","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Yeditepe University, Istanbul, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol."},{"key":"R2-20230912","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc."},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J Clin Invest."},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.biocel.2006.03.010","article-title":"The keratocyte: corneal stromal cell with variable repair phenotypes","volume":"38","author":"West-Mays","year":"2006","journal-title":"Int J Biochem Cell Biol."},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"19461","DOI":"10.1016\/S0021-9258(17)45395-6","article-title":"Characterization of the receptors for vascular endothelial growth factor","volume":"265","author":"Vaisman","year":"1990","journal-title":"J Biol Chem."},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res."},{"key":"R7-20230912","first-page":"323","article-title":"Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea","volume":"31","author":"Soubrane","year":"1990","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R8-20230912","first-page":"637","article-title":"Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells","volume":"34","author":"Hoppenreijs","year":"1993","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol."},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1167\/iovs.05-1071","article-title":"The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization","volume":"47","author":"Dell","year":"2006","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bcp.12371","article-title":"Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future","volume":"78","author":"Kwong","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","article-title":"Effect of bevacizumab on corneal neovascularization in experimental rabbit model","volume":"37","author":"Ahmed","year":"2009","journal-title":"Clin Exp Ophthalmol."},{"key":"R13-20230912","first-page":"448","article-title":"Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model","volume":"5","author":"Dursun","year":"2012","journal-title":"Int J Ophthalmol."},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Exp Ophthalmol."},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res."},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon.14.208","article-title":"Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity","volume":"11","author":"Porta","year":"2015","journal-title":"Future Oncol."},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00280-013-2139-4","article-title":"Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma","volume":"71","author":"Chan","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2011.09.017","article-title":"Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma","volume":"56","author":"Huynh","year":"2012","journal-title":"J Hepatol."},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br J Ophthalmol."},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/ICO.0b013e31823f8b9c","article-title":"Inhibition of corneal neovascularization in rats by systemic administration of sorafenib","volume":"31","author":"Seo","year":"2012","journal-title":"Cornea"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model","volume":"150","author":"P\u00e9rez-Santonja","year":"2010","journal-title":"Am J Ophthalmol."},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1167\/iovs.12-11032","article-title":"Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization","volume":"54","author":"Amparo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R23-20230912","first-page":"220","article-title":"Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization","volume":"7","author":"Onder","year":"2014","journal-title":"Int J Ophthalmol."},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/ICO.0b013e3182801645","article-title":"Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model","volume":"32","author":"Ko","year":"2013","journal-title":"Cornea"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","article-title":"CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia","volume":"11","author":"Lopes de Menezes","year":"2005","journal-title":"Clin Cancer Res."},{"key":"R26-20230912","first-page":"72","article-title":"Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer","volume":"5","author":"Lee","year":"2015","journal-title":"Am J Cancer Res."},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"e94205","DOI":"10.1371\/journal.pone.0094205","article-title":"Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4172\/1948-5956.1000235","article-title":"Regulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitors","volume":"5","author":"Gunda","year":"2013","journal-title":"J Cancer Sci Ther."},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10520295.2017.1371333","article-title":"Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn","volume":"92","author":"Altan","year":"2017","journal-title":"Biotech Histochem."},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1208\/ps040102","article-title":"Ocular tolerance of absorption enhancers in ophthalmic preparations","volume":"4","author":"Furrer","year":"2002","journal-title":"AAPS PharmSci."},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:29:29Z","timestamp":1694546969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000002012","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,5]]}}}